SCHEMBL4673446

SCHEMBL4673446

O=C(C=C(O)c1nn[nH]n1)c1cc(Cc2ccccc2F)cs1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.35
NCEH1 Q6PIU2 1/20 0.35
PTPN1 P18031 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
MMEL1 Q495T6 2/20 0.33
DAO P14920 1/20 0.33
HCAR3 P49019 1/20 0.32
ERCC5 P28715 1/20 0.32
FEN1 P39748 1/20 0.32
MME P08473 1/20 0.32
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
ABL1 P00519 1/20 0.31
ELOVL1 Q9BW60 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
CXCR3 P49682 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676614 0.87 CES1 (0.41) CES1NCEH1PTGDR2MMEL1DAO
SCHEMBL4671773 0.85 MAPT (0.35) CES1NCEH1PTGDR2MMEL1MME
SCHEMBL4677639 0.84 HCAR2 (0.39) CES1NCEH1PTGDR2DAOLMNA
SCHEMBL4677065 0.84 PTPN1 (0.34) PTPN1DAOHCAR3LMNAHPGD
SCHEMBL4680230 0.82 PTGDR2 (0.36) CES1NCEH1PTPN1PTGDR2MMEL1
SCHEMBL4674973 0.82 CES1 (0.35) CES1NCEH1MMEL1DAOERCC5
SCHEMBL4675638 0.82 ABL1 (0.35) CES1NCEH1PTGDR2MMEL1HCAR3
SCHEMBL4671549 0.81 MAPT (0.35) CES1NCEH1DAOMAPTNPSR1
SCHEMBL4670701 0.81 CES1 (0.35) CES1NCEH1PTPN1PTGDR2MMEL1
SCHEMBL4671730 0.81 MAPT (0.37) CES1NCEH1MMEL1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885PTPN1 2715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.